AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
HILTON HEAD ISLAND, S.C. -- Patients treated with oxybutynin for incontinence due to overactive bladder experience fewer side effects but similar benefits when the drug is delivered via an experimental transdermal patch rather than a pill.
"With the patch, we're changing the metabolism of oxybutynin. It's not being metabolized in the gut and the liver, which is the reason for less side effects," Dr. Willy G. Davila said at the annual meeting of the American Urogynecologic Society.
Dry mouth is the most commonly reported side effect associated with oral oxybutynin treatment, according to Dr. Davila, principal investigator of the study sponsored by Watson Pharmaceuticals Inc., which makes the drug.
In a phase II, double-blind study of 74 patients randomized to 6 weeks of treatment with either the oxybutynin patch or oral oxybutynin, Dr. Davila noted a significantly lower incidence of dry mouth in the patch group (39% vs. 82%).
Furthermore, none of the ...
Source: HighBeam Research, Fewer Side Effects Noted With Experimental Oxybutynin Patch.